ONC:CC News and Press, Oncolytics Biotech Inc.

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...

2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, s...

2024-06-20 10:00:19 ET Palm Beach, FL – June 20, 2024 –  The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: “… the increa...

2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...

2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024  – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer PR Newswire Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may bene...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the w...